<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998049</url>
  </required_header>
  <id_info>
    <org_study_id>MC0889</org_study_id>
    <secondary_id>NCI-2009-01328</secondary_id>
    <secondary_id>MC0889</secondary_id>
    <secondary_id>08-005644</secondary_id>
    <nct_id>NCT00998049</nct_id>
  </id_info>
  <brief_title>Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant</brief_title>
  <official_title>Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Giving colony-stimulating factors, such as G-CSF and plerixafor helps stem cells
      move from the patient's bone marrow to the blood so they can be collected and stored.
      Purpose: This phase II trial is studying how well plerixafor works in patients with multiple
      myeloma previously treated with lenalidomide and planning to undergo autologous stem cell
      transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: I. To determine the proportion of patients reaching a stem cell yield of 3
      million CD34 cells/kg by second day of apheresis with intravenously administered AMD3100
      among patients receiving primary therapy for myeloma with lenalidomide. Secondary Objectives:
      I. Safety and tolerability of intravenously administered AMD3100. II. Rate of failure to
      mobilize. Outline: Patients receive plerixafor IV on days 5-8 and filgrastim subcutaneously
      on days 1-8 in the absence of disease progression or unacceptable toxicity. After completion
      of study treatment, patients are followed at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Achieving 3 Million CD34 Cells/kg After 2 Days of Apheresis</measure>
    <time_frame>After 2 days of apheresis</time_frame>
    <description>Number of CD34 cells/kg collected on days 1-2.
Apheresis is the process when blood is taken out through a catheter in a vein in one arm, blood is sent through a machine that takes out the stem cells and the rest of the blood is then returned through a vein in your other arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD34 Yield on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of CD34 cells/kg collected on day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34 Yield Day 2</measure>
    <time_frame>Day 2</time_frame>
    <description>Number of CD34 cells/kg collected on day 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Days of Apheresis</measure>
    <time_frame>Duration of apheresis (up to 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach 6 Million CD34 Cells</measure>
    <time_frame>Duration of apheresis (up to 7 days)</time_frame>
    <description>Number (median and 95% confidence interval) of days to reach 6 million CD34 cells/kg was estimated using the Kaplan Meier method. Participants were lower than 6 million CD34 cells/kg at time of last follow-up will be censored at that date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Failure to Mobilize</measure>
    <time_frame>Duration of apheresis (up to 7 days)</time_frame>
    <description>The rate of failure to mobilize will be estimated by dividing the number of patients that fail to mobilize by the total number of evaluable patients. A patient is considered a failure if they never achieve 2.5 million CD34 cells/kg.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Plerixafor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>plerixafor</intervention_name>
    <description>Plerixafor 160mg/kg/dose by IV on days 5-8</description>
    <arm_group_label>Plerixafor</arm_group_label>
    <other_name>AMD 3100</other_name>
    <other_name>LM-3100</other_name>
    <other_name>Mozobil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
    <arm_group_label>Plerixafor</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>granulocyte colony-stimulating factor</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion - Absolute neutrophil count &gt;= 1000/uL - Platelet &gt;= 75000/uL - Hemoglobin &gt;= 8.0
        g/dL - Serum aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase
        (SGOT), serum alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) and
        total bilirubin &lt; 2 x upper limit of normal (ULN) - Confirmed diagnosis of multiple
        myeloma, requiring therapy - Initial treatment for symptomatic myeloma using a lenalidomide
        based treatment regimen, started =&lt; 12 months prior to registration - Received at least 2
        cycles of treatment with the lenalidomide regimen - Last dose of lenalidomide &gt; 2 weeks
        prior to registration - Eligible to undergo autologous transplantation - ECOG performance
        status (PS) 0 or 1 - Willingness to return for follow-up - Provide informed written consent
        - Adequate cardiopulmonary function: ejection fraction &gt;= 45%, corrected pulmonary
        diffusion capacity of &gt;= 50%, FEV1 &gt;= 50%, FVC &gt;= 50% - Negative serum or urine pregnancy
        test done =&lt; 7 days prior to registration, for women of childbearing potential only
        Exclusion - A co-morbid condition which, in the view of the Investigators, renders the
        patient at high risk from treatment complications - Active malignancy with the exception of
        non melanoma skin cancer or in situ cervical or breast cancer - Other co-morbidity which
        would interfere with patient's ability to participate in the trial, e.g. uncontrolled
        infection, uncompensated heart or lung disease - Other concurrent chemotherapy,
        radiotherapy, or any ancillary therapy considered investigational - Use of cyclophosphamide
        as part of stem cell mobilization - Use of more than one regimen for treatment of
        symptomatic myeloma - Dialysis dependent renal failure - Pregnant women or women of
        reproductive ability who are unwilling to use effective contraception - Nursing women - Men
        who are unwilling to use a condom (even if they have undergone a prior vasectomy) while
        having intercourse with any woman, while taking the drug and for 4 weeks after stopping
        treatment - Acute infection, active HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaji Kumar, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph R. Mikhael, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <results_first_submitted>June 26, 2012</results_first_submitted>
  <results_first_submitted_qc>June 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2012</results_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Forty (40) participants were recruited at Mayo Clinic (Rochester, Florida and Arizona) between December 2009 and October 2011.</recruitment_details>
      <pre_assignment_details>One participant was deemed ineligible and is excluded from all analyses per study design.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Plerixafor</title>
          <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Plerixafor</title>
          <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="28" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Achieving 3 Million CD34 Cells/kg After 2 Days of Apheresis</title>
        <description>Number of CD34 cells/kg collected on days 1-2.
Apheresis is the process when blood is taken out through a catheter in a vein in one arm, blood is sent through a machine that takes out the stem cells and the rest of the blood is then returned through a vein in your other arm.</description>
        <time_frame>After 2 days of apheresis</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plerixafor</title>
            <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving 3 Million CD34 Cells/kg After 2 Days of Apheresis</title>
          <description>Number of CD34 cells/kg collected on days 1-2.
Apheresis is the process when blood is taken out through a catheter in a vein in one arm, blood is sent through a machine that takes out the stem cells and the rest of the blood is then returned through a vein in your other arm.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD34 Yield on Day 1</title>
        <description>Number of CD34 cells/kg collected on day 1.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plerixafor</title>
            <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
          </group>
        </group_list>
        <measure>
          <title>CD34 Yield on Day 1</title>
          <description>Number of CD34 cells/kg collected on day 1.</description>
          <units>cells/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3870000" lower_limit="670000" upper_limit="9160000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD34 Yield Day 2</title>
        <description>Number of CD34 cells/kg collected on day 2</description>
        <time_frame>Day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plerixafor</title>
            <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
          </group>
        </group_list>
        <measure>
          <title>CD34 Yield Day 2</title>
          <description>Number of CD34 cells/kg collected on day 2</description>
          <units>cells/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3550000" lower_limit="470000" upper_limit="9170000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Days of Apheresis</title>
        <time_frame>Duration of apheresis (up to 7 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plerixafor</title>
            <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Days of Apheresis</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach 6 Million CD34 Cells</title>
        <description>Number (median and 95% confidence interval) of days to reach 6 million CD34 cells/kg was estimated using the Kaplan Meier method. Participants were lower than 6 million CD34 cells/kg at time of last follow-up will be censored at that date.</description>
        <time_frame>Duration of apheresis (up to 7 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plerixafor</title>
            <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach 6 Million CD34 Cells</title>
          <description>Number (median and 95% confidence interval) of days to reach 6 million CD34 cells/kg was estimated using the Kaplan Meier method. Participants were lower than 6 million CD34 cells/kg at time of last follow-up will be censored at that date.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Failure to Mobilize</title>
        <description>The rate of failure to mobilize will be estimated by dividing the number of patients that fail to mobilize by the total number of evaluable patients. A patient is considered a failure if they never achieve 2.5 million CD34 cells/kg.</description>
        <time_frame>Duration of apheresis (up to 7 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plerixafor</title>
            <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Failure to Mobilize</title>
          <description>The rate of failure to mobilize will be estimated by dividing the number of patients that fail to mobilize by the total number of evaluable patients. A patient is considered a failure if they never achieve 2.5 million CD34 cells/kg.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit=".006" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Plerixafor</title>
          <description>Plerixafor 160mg/kg/dose by IV on days 5-8
Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shaji Kumar</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>kumar.shaji@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

